Dose-dense chemotherapy for aggressive non-Hodgkin lymphoma.
Non-Hodgkin lymphoma is a heterogeneous disease that represents the seventh leading cause of cancer death. Second-generation and third-generation chemotherapy regimens have only produced a marginal improvement in outcome over the administration of the cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in aggressive forms of non-Hodgkin lymphoma. This has led to the development of different strategies for improving disease-free and overall survival in this disease. Dose intensification achieved by condensing the intervals between each chemotherapy cycle is possible with granulocyte colony-stimulating factor support, which reduces neutropenia and its complications. Clinical trials indicate that this strategy may improve the outcomes in patients with aggressive non-Hodgkin lymphoma, particularly elderly patients. Nurses can play a major role in the implementation of evidence-based supportive care strategies in clinical practice to ensure safe use of dose-dense chemotherapy regimens.
Anderson-Reitz
Lowell
L
Baylor-Charles A. Sammons Cancer Center, Dallas, TX 75246, USA. lowell.anderson-reitz@usoncology.com
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D017053:Infection Control; D007239:Infections / Q000139:chemically induced; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D024802:Nurse's Role; D009859:Oncology Nursing / Q000458:organization & administration; D011241:Prednisone / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone